Christopher Yea Kal Vista Pharmaceuticals, Inc. (KALV) insider trading activity

Christopher Yea is CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 92,745 shares of KALV, which is worth approximately $930,232. The most recent transaction as insider was on Feb 18, 2025, when has been sold 2,601 shares (Common Stock) at a price of $9.82 per share, resulting in proceeds of $25,541. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 92.7K

0.39% 3M change

27.23% 12M change

Total Value Held $930,232

Christopher Yea Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	SELL Open market or private sale	$25,541 $9.82 p/Share	2,601 Reduced 2.73%	92,745 Common Stock
Feb 17 2025	BUY Exercise of conversion of derivative security	-	4,204 Added 4.22%	95,346 Common Stock
Nov 26 2024	SELL Open market or private sale	$19,374 $9.87 p/Share	1,963 Reduced 2.11%	91,142 Common Stock
Nov 22 2024	BUY Exercise of conversion of derivative security	-	3,125 Added 3.25%	93,105 Common Stock
Nov 18 2024	SELL Open market or private sale	$66,597 $9.26 p/Share	7,192 Reduced 7.4%	89,980 Common Stock
Nov 17 2024	BUY Exercise of conversion of derivative security	-	11,496 Added 10.58%	97,172 Common Stock
Aug 23 2024	SELL Open market or private sale	$23,758 $12.4 p/Share	1,916 Reduced 2.19%	85,676 Common Stock
Aug 22 2024	BUY Exercise of conversion of derivative security	-	3,125 Added 3.44%	87,592 Common Stock
Aug 19 2024	SELL Open market or private sale	$85,295 $12.01 p/Share	7,102 Reduced 7.76%	84,467 Common Stock
Aug 17 2024	BUY Exercise of conversion of derivative security	-	11,495 Added 11.15%	91,569 Common Stock
May 20 2024	SELL Open market or private sale	$136,533 $11.76 p/Share	11,610 Reduced 12.66%	80,074 Common Stock
May 17 2024	BUY Exercise of conversion of derivative security	-	18,789 Added 17.01%	91,684 Common Stock
Feb 20 2024	SELL Open market or private sale	$170,067 $14.11 p/Share	12,053 Reduced 14.19%	72,895 Common Stock
Feb 17 2024	BUY Exercise of conversion of derivative security	-	18,788 Added 18.11%	84,948 Common Stock
Feb 14 2024	SELL Open market or private sale	$598,688 $15.01 p/Share	39,886 Reduced 37.61%	66,160 Common Stock
Feb 11 2024	BUY Grant, award, or other acquisition	-	60,000 Added 36.13%	106,046 Common Stock
Nov 20 2023	SELL Open market or private sale	$58,539 $8.23 p/Share	7,113 Reduced 13.38%	46,046 Common Stock
Nov 17 2023	BUY Exercise of conversion of derivative security	-	11,497 Added 17.78%	53,159 Common Stock
Aug 18 2023	SELL Open market or private sale	$76,633 $10.73 p/Share	7,142 Reduced 14.63%	41,662 Common Stock
Aug 17 2023	BUY Exercise of conversion of derivative security	-	11,494 Added 19.06%	48,804 Common Stock
May 18 2023	SELL Open market or private sale	$26,404 $10.14 p/Share	2,604 Reduced 6.52%	37,310 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	-	4,205 Added 9.53%	39,914 Common Stock
Feb 17 2023	SELL Open market or private sale	$20,888 $7.66 p/Share	2,727 Reduced 7.09%	35,709 Common Stock
Feb 17 2023	BUY Exercise of conversion of derivative security	-	4,204 Added 9.86%	38,436 Common Stock
Nov 18 2022	SELL Open market or private sale	$6,196 $5.44 p/Share	1,139 Reduced 3.22%	34,232 Common Stock

Christopher Yea

CHIEF DEVELOPMENT OFFICER

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Value

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

Operation

Value

Type

News

Receive news related to KalVista Pharmaceuticals, Inc.

Track Activities on KALV

Account